Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 1439

Sort by

Sort Order Select

Journal Articles

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Atte Nikkilä, MD, Olli Lohi, MD PhD, Ólafur Gísli Jónsson, MD PhD, Bendik Lund, MD PhD, Jonas Abrahamsson, Goda Elizabeta Vaitkeviciene, MD PhD, Kaie Pruunsild, MD, Mats Heyman, MD PhD, Hanne Vibeke Marquart, MD PhD, Kim Vettenranta, MD PhD, Kjeld Schmiegelow, MD PhD

Blood (2019) 134 (Supplement_1): 742.

https://doi.org/10.1182/blood-2019-122914

Published: 2019

Journal Articles

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Geffen Kleinstern, PhD, Daniel R O'Brien, Brian Kabat, B.S., Kari G Rabe, Aaron D. Norman, Huihuang Yan, PhD, Celine M. Vachon, PhD, Shulan Tian, MS, PhD, Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Esteban Braggio, PhD, Susan L. Slager, PhD

Blood (2019) 134 (Supplement_1): 852.

https://doi.org/10.1182/blood-2019-124346

Published: 2019

Journal Articles

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Ravi K Goyal, MS, Saurabh P Nagar, MS, Shaum M Kabadi, PhD MPH, Keith L Davis, MA, Hannah Le, PharmD, MPH, James A Kaye, MD

Blood (2019) 134 (Supplement_1): 796.

https://doi.org/10.1182/blood-2019-122842

Published: 2019

Journal Articles

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

Blood (2019) 134 (Supplement_1): 1302.

https://doi.org/10.1182/blood-2019-124882

Published: 2019

Journal Articles

The Study of Thrombosis in JAK2 V617F Mutated Myeloproliferative Neoplasms

Jie Bai, MD, Yuhui Zhang, Yingshao Wang, Guangshuai Teng, Yan Wang, Chenxiao Du, Yafang Chen, Huiqin Zhang, Yanqi Li, Lixia Fu, Lei Zhang, MD, Yuan Zhou, PhD

Blood (2019) 134 (Supplement_1): 1149.

https://doi.org/10.1182/blood-2019-125429

Published: 2019

Journal Articles

N6-Methyladenosine RNA Methylation Regulators Contribute to Malignant Progression and Survival Prediction in Chronic Lymphocytic Leukemia

Ya Zhang, MD, Xiaosheng Fang, PhD, Na Chen, MD, Xiao Lv, PhD, Xueling Ge, PhD, Kang Lu, MD PhD, Xiangxiang Zhou, MD, Juan Yang, MM, Yang Han, MM, Shunfeng Hu, Xin Wang, MD PhD

Blood (2019) 134 (Supplement_1): 1738.

https://doi.org/10.1182/blood-2019-126469

Published: 2019

Journal Articles

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Moritz Binder, MDMPH, S. Vincent Rajkumar, MD, Martha Q. Lacy, MD, Jessica L. Haug, Angela Dispenzieri, MD, Kimberly J. Henderson, Teresa K. Kimlinger, Shaji K. Kumar, MD

Blood (2019) 134 (Supplement_1): 1772.

https://doi.org/10.1182/blood-2019-123407

Published: 2019

Journal Articles

Risk of Progression in Patients with Smoldering Myeloma

Fahrettin Covut, MD, Kamal Chamoun, MD, Leland Metheny, III, MD, Kirsten M Boughan, DO, James Driscoll, MD PhD, Marcos de Lima, MD, Ehsan Malek, MD

Blood (2019) 134 (Supplement_1): 1892.

https://doi.org/10.1182/blood-2019-127677

Published: 2019

Journal Articles

Percentage of Infiltrating T Lymphocytes in Diffuse Large B-Cell Lymphoma Lymph Nodes Measured By Flow Cytometry Predicts Overall Survival and Provides Additional Prognostic Information When Combined with the R-IPI

Laura Korin, MD, Maria Del Rosario Custidiano, MD, Maria Lucia Fuente, Santiago Cranco, MD, Adriana Vitriu, MD, Paola Ochoa, MD, Evelina Babuin, Fernando Diaz Couselo, MD, Anahí Vijnovich Baron, MD, Paula Tempra, Maria Belen Venegas, Andrea Novoa, Norma Elisabeth Tartas, MD, Maria Cecilia Foncuberta, MD, Julio Cesar Sanchez Avalos, MD

Blood (2019) 134 (Supplement_1): 1625.

https://doi.org/10.1182/blood-2019-126193

Published: 2019

Journal Articles

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

Alex G Sieg, MD MS, Christopher Strouse, MD, Sarah L Mott, Joshua Reeder, Sergei Syrbu, MD PhD, Guohua An, MD PhD, Grerk Sutamtewagul, MD, Brian K. Link, MD, Umar Farooq, MD

Blood (2019) 134 (Supplement_1): 1626.

https://doi.org/10.1182/blood-2019-127349

Published: 2019

Journal Articles

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

Anthony M. Hunter, MD, Najla Al Ali, M.Sc, David A Sallman, MD, Kendra L. Sweet, MD, Andrew T Kuykendall, MD, Chetasi Talati, MD, Alan F. List, MD, Jeffrey E. Lancet, MD, Rami S. Komrokji, MD, Eric Padron, MD

Blood (2019) 134 (Supplement_1): 1717.

https://doi.org/10.1182/blood-2019-131071

Published: 2019

Journal Articles

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Rashmi Kanagal-Shamanna, MD, Guillermo Montalban-Bravo, MD, Caleb Class, PhD, Koji Sasaki, MD, Christopher B. Benton, MD, Kelly Soltysiak, PhD, Elias Jabbour, MD, Tapan M. Kadia, MD, Carlos E. Bueso-Ramos, MD PhD, Keyur P. Patel, MBBS, PhD, Mark Routbort, MD PhD, Irene Ganan-Gomez, PhD, Yue Wei, PhD, Gautam M. Borthakur, MD, Farhad Ravandi, MD, Kim-Anh Do, PhD, L. Jeffrey Medeiros, MD, Hagop M. Kantarjian, MD, Guillermo Garcia-Manero, MD

Blood (2019) 134 (Supplement_1): 1719.

https://doi.org/10.1182/blood-2019-130545

Published: 2019

Journal Articles

Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database

Ravi Kishore Narra, MD MBBS, Ehab L. Atallah, MD, Mehdi Hamadani, MD, Guru Subramanian Guru Guru Murthy, MBBS

Blood (2019) 134 (Supplement_1): 1757.

https://doi.org/10.1182/blood-2019-130211

Published: 2019

Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD

Blood (2019) 134 (Supplement_1): 1867.

https://doi.org/10.1182/blood-2019-125629

Published: 2019

Journal Articles

Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients

Nicola Polverelli, Paolo Tura, Giorgia Battipaglia, MD, Gandolfi Lisa, Tatiana Zollner, MD, Michele Malagola, MD, Enrico Morello, MD, Alessandro Turra, MD, Simona Bernardi, PhD, Camilla Zanaglio, PhD, Federica Re, Mohamad Mohty, MD PhD, Domenico Russo, MD

Blood (2019) 134 (Supplement_1): 41.

https://doi.org/10.1182/blood-2019-127026

Published: 2019

Journal Articles

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Simone Claudiani, MD, Silvia Metelli, PhD, Rafiee Kamvar, BSc, Richard Szydlo, PhD, Afzal Khan, Jenny Byrne, MD PhD, Paolo Gallipoli, PhD, Simon J Bulley, Gillian A. Horne, MBChB BSc, MRCP, MRes, PhD, Kate Rothwell, BA MB BChir, PhD, Mhairi Copland, PhD MBBChir, FRCP, FRCPath, Richard E. Clark, MA, MD MRCP, FRCPath, Jamshid S Khorashad, MD PhD, Letizia Foroni, MD PhD, Dragana Milojkovic, MBBS, MD, Jane F. Apperley, MD FRCP, FRCPath, MB

Blood (2019) 134 (Supplement_1): 26.

https://doi.org/10.1182/blood-2019-131500

Published: 2019

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Aggressive Natural Killer Cell Leukemia: An Advantage of Cord Blood Transplantation

Ayumi Fujimoto, MD, Fumihiro Ishida, MD PhD, Koji Izutsu, MD PhD, Satoshi Yamasaki, MD PhD, Dai Chihara, MD PhD, Junji Suzumiya, MD PhD, Tetsuo Mitsui, MD PhD, Kazuteru Ohashi, MD PhD, Hideyuki Nakazawa, MD PhD, Hikaru Kobayashi, MD PhD, Junya Kanda, MD, Takahiro Fukuda, Yoshiko Atsuta, MD PhD, Ritsuro Suzuki, MD PhD

Blood (2019) 134 (Supplement_1): 2032.

https://doi.org/10.1182/blood-2019-122049

Published: 2019

Journal Articles

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Abby Statler, PhDMPH, Brian P. Hobbs, PhD, Tomas Radivoyevitch, PhD, Caitlin Siebenaller, PharmD, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aaron T. Gerds, MD MS, Aziz Nazha, MD, Bhumika J. Patel, MD, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS

Blood (2019) 134 (Supplement_1): 16.

https://doi.org/10.1182/blood-2019-130319

Published: 2019

Journal Articles

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Hiroyuki Muranushi, MD, Takero Shindo, MD PhD, Masakatsu Hishizawa, MD PhD, Masahito Tokunaga, MD PhD, Atsushi Wake, MD PhD, Nobuaki Nakano, MD, Tetsuya Eto, MD PhD, Michihiro Hidaka, MD PhD, Ilseung Choi, MD PhD, Toshihiro Miyamoto, MD PhD, Naoyuki Uchida, MD PhD, Yukiyoshi Moriuchi, MD, Yasuhiko Miyazaki, MD PhD, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, MD PhD, Koji Kato, MD PhD

Blood (2019) 134 (Supplement_1): 2008.

https://doi.org/10.1182/blood-2019-123318

Published: 2019

Journal Articles

Disease Risk Index (DRI) and Age but Not HCT Comorbidity Index (HCT-CI) Are Predictive of Overall Survival after Cord Blood Transplantation Supported By Haplo-CD34 + progenitor Cells

Alexandra Gomez-Arteaga, MD, Nina Orfali, MB,PhD, Danielle Guarneri, BS, CCRP, Usama Gergis, MD MBA, Sebastian A. Mayer, MD, Jingmei Hsu, MD, Adrienne A. Phillips, MD MPH, Tsiporah B. Shore, MD, Koen Van Besien, MD PhD

Blood (2019) 134 (Supplement_1): 2040.

https://doi.org/10.1182/blood-2019-129584

Published: 2019

NARROW

Intensive Chemotherapy for High-Risk ALL in Children - the Nordic Collaborative Approach

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Overall Survival, Adverse Events, and Economic Burden in Medicare Patients with Chronic Lymphocytic Leukemia Receiving Cancer-Directed Therapy

Real World Outcomes of Adult B-Cell Acute Lymphocytic Leukemia Patients Treated with Inotuzumab Ozogamicin

The Study of Thrombosis in JAK2 V617F Mutated Myeloproliferative Neoplasms

N6-Methyladenosine RNA Methylation Regulators Contribute to Malignant Progression and Survival Prediction in Chronic Lymphocytic Leukemia

The Transcriptome of Immunomodulator-Resistant Multiple Myeloma

Risk of Progression in Patients with Smoldering Myeloma

Percentage of Infiltrating T Lymphocytes in Diffuse Large B-Cell Lymphoma Lymph Nodes Measured By Flow Cytometry Predicts Overall Survival and Provides Additional Prognostic Information When Combined with the R-IPI

Methotrexate and Area Under the Curve Exposure in Patients Receiving MT-R for Primary CNS Lymphoma: A Single Institution Retrospective Study

WHO-Defined Chronic Myelomonocytic Leukemia-2 (CMML-2) Patients Rapidly Progress to AML Suggesting This Entity Represents a Transitory Clinical State

Evolutionary Action (EA) Score of TP53 Mutations Defines Prognostic Subsets within TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Population Level Outcomes of Chronic Lymphocytic Leukemia in the Era of Targeted Agents- Analysis of Surveillance Epidemiology and End Results (SEER) Database

Multidimensional Geriatric Assessment for Elderly Patients (≥60 years) Submitted for Allogeneic Stem Cell Transplantation. a French (Paris) - Italian (Brescia) 10-Years Experience on 228 Patients

Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)

Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Aggressive Natural Killer Cell Leukemia: An Advantage of Cord Blood Transplantation

The Impact of Comorbidities and Organ Dysfunction Commonly Used for Clinical Trial Eligibility Criteria on Outcome in Acute Myeloid Leukemia (AML) Patients Receiving Induction Chemotherapy

Graft-Versus-Host Disease-Free, Relapse-Free Survival in Allogeneic Stem Cell Transplantation for Adult T-Cell Leukemia/Lymphoma Provides a Novel Donor Selection Paradigm

Disease Risk Index (DRI) and Age but Not HCT Comorbidity Index (HCT-CI) Are Predictive of Overall Survival after Cord Blood Transplantation Supported By Haplo-CD34 + progenitor Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only